Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech is set to commence enrollment for a new pancreatic cancer cohort in their GOBLET study, investigating the efficacy of pelareorep in combination with modified FOLFIRINOX and possibly atezolizumab. The study, backed by a US$5 million grant from the Pancreatic Cancer Action Network, aims to improve treatment options for patients with pancreatic ductal adenocarcinoma. Early positive results and strategic focus on widely used treatment regimens could accelerate the development of new therapies for pancreatic cancer.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
